Study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening [Yahoo! Finance]
VolitionRX Limited (VNRX)
NASDAQ:AMEX Investor Relations:
ir.volitionrx.com
Company Research
Source: Yahoo! Finance
announced the results of a large-scale study which shows that its Nu.Q ® Cancer Test differentiated between malignant and benign pulmonary nodules, found by Low Dose CT ( LDCT ) scan, in patients suspected of lung cancer. The 800-patient prospective study was led by Professor Jin-Shing Chen and his team at National Taiwan University Hospital. Findings published in a paper that is currently undergoing peer review and accessible on MedRXIV, conclude that a panel of two Nu.Q® nucleosome quantification assays (H3.1 and H3K27Me3) showed a diagnostic sensitivity of 92% and a Positive Predictive Value of 89% in identifying cancerous nodules when used in combination with LDCT screening. Professor Chen, Department Chief, Department of Surgery, National Taiwan University Hospital, said: "Lung cancer is a leading cause of cancer-related deaths globally. LDCT is the gold standard for lung cancer screening and has been instrumental in reducing mortality in high-risk patients. However, it i
Show less
Read more
Impact Snapshot
Event Time:
VNRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VNRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VNRX alerts
High impacting VolitionRX Limited news events
Weekly update
A roundup of the hottest topics
VNRX
News
- VolitionRx Limited (NYSE: VNRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- VolitionRx Limited (NYSE: VNRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- VolitionRx Appoints LifeSci Advisors as Investor Relations Consultants [Yahoo! Finance]Yahoo! Finance
- VolitionRx Appoints LifeSci Advisors as Investor Relations ConsultantsPR Newswire
- VolitionRx Limited (NYSE: VNRX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.MarketBeat
VNRX
Earnings
- 11/14/24 - In-Line
VNRX
Sec Filings
- 12/10/24 - Form 4
- 12/10/24 - Form 4
- 12/10/24 - Form 4
- VNRX's page on the SEC website